Compile Data Set for Download or QSAR
Report error Found 39 Enz. Inhib. hit(s) with all data for entry = 10030
TargetTyrosine-protein kinase JAK3(Human)
Celon Pharma

US Patent
LigandPNGBDBM509527(US11072619, Example 11)
Affinity DataIC50: 0.0300nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Celon Pharma

US Patent
LigandPNGBDBM509527(US11072619, Example 11)
Affinity DataIC50: 0.0500nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Celon Pharma

US Patent
LigandPNGBDBM509520(US11072619, Example 6)
Affinity DataIC50: 0.160nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Celon Pharma

US Patent
LigandPNGBDBM509521(US11072619, Example 7)
Affinity DataIC50: 0.190nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Celon Pharma

US Patent
LigandPNGBDBM509529(US11072619, Example 13)
Affinity DataIC50: 0.200nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Celon Pharma

US Patent
LigandPNGBDBM509528(US11072619, Example 12)
Affinity DataIC50: 0.290nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Celon Pharma

US Patent
LigandPNGBDBM509520(US11072619, Example 6)
Affinity DataIC50: 0.380nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Celon Pharma

US Patent
LigandPNGBDBM509529(US11072619, Example 13)
Affinity DataIC50: 0.510nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Celon Pharma

US Patent
LigandPNGBDBM509528(US11072619, Example 12)
Affinity DataIC50: 0.510nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Celon Pharma

US Patent
LigandPNGBDBM509526(US11072619, Example 10)
Affinity DataIC50: 0.600nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Celon Pharma

US Patent
LigandPNGBDBM509521(US11072619, Example 7)
Affinity DataIC50: 0.75nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Celon Pharma

US Patent
LigandPNGBDBM509527(US11072619, Example 11)
Affinity DataIC50: 1.18nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Celon Pharma

US Patent
LigandPNGBDBM509515(US11072619, Example 1 | (R)-7-((1-(6-Cyanopyridazi...)
Affinity DataIC50: 1.20nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Celon Pharma

US Patent
LigandPNGBDBM509517(US11072619, Example 3 | (R)-7-((1-(6-Cyanopyridazi...)
Affinity DataIC50: 1.58nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Celon Pharma

US Patent
LigandPNGBDBM509519(US11072619, Example 5)
Affinity DataIC50: 1.80nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Celon Pharma

US Patent
LigandPNGBDBM509515(US11072619, Example 1 | (R)-7-((1-(6-Cyanopyridazi...)
Affinity DataIC50: 1.80nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Celon Pharma

US Patent
LigandPNGBDBM509522(US11072619, Example 8)
Affinity DataIC50: 2.24nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Celon Pharma

US Patent
LigandPNGBDBM509526(US11072619, Example 10)
Affinity DataIC50: 2.37nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Celon Pharma

US Patent
LigandPNGBDBM509518(US11072619, Example 4)
Affinity DataIC50: 2.67nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Celon Pharma

US Patent
LigandPNGBDBM509518(US11072619, Example 4)
Affinity DataIC50: 2.67nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Celon Pharma

US Patent
LigandPNGBDBM509529(US11072619, Example 13)
Affinity DataIC50: 2.82nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Celon Pharma

US Patent
LigandPNGBDBM509520(US11072619, Example 6)
Affinity DataIC50: 2.98nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Celon Pharma

US Patent
LigandPNGBDBM509521(US11072619, Example 7)
Affinity DataIC50: 3.40nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Celon Pharma

US Patent
LigandPNGBDBM509516(US11072619, Example 2)
Affinity DataIC50: 3.74nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Celon Pharma

US Patent
LigandPNGBDBM509516(US11072619, Example 2)
Affinity DataIC50: 3.77nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Celon Pharma

US Patent
LigandPNGBDBM509517(US11072619, Example 3 | (R)-7-((1-(6-Cyanopyridazi...)
Affinity DataIC50: 4.47nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Celon Pharma

US Patent
LigandPNGBDBM509528(US11072619, Example 12)
Affinity DataIC50: 5.05nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Celon Pharma

US Patent
LigandPNGBDBM509519(US11072619, Example 5)
Affinity DataIC50: 8.08nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Celon Pharma

US Patent
LigandPNGBDBM509522(US11072619, Example 8)
Affinity DataIC50: 8.54nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Celon Pharma

US Patent
LigandPNGBDBM509526(US11072619, Example 10)
Affinity DataIC50: 12.8nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Celon Pharma

US Patent
LigandPNGBDBM509525(US11072619, Example 9)
Affinity DataIC50: 18.8nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Celon Pharma

US Patent
LigandPNGBDBM509515(US11072619, Example 1 | (R)-7-((1-(6-Cyanopyridazi...)
Affinity DataIC50: 19nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Celon Pharma

US Patent
LigandPNGBDBM509522(US11072619, Example 8)
Affinity DataIC50: 26.8nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Celon Pharma

US Patent
LigandPNGBDBM509518(US11072619, Example 4)
Affinity DataIC50: 27.7nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Celon Pharma

US Patent
LigandPNGBDBM509517(US11072619, Example 3 | (R)-7-((1-(6-Cyanopyridazi...)
Affinity DataIC50: 31.1nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Celon Pharma

US Patent
LigandPNGBDBM509519(US11072619, Example 5)
Affinity DataIC50: 34.4nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Celon Pharma

US Patent
LigandPNGBDBM509525(US11072619, Example 9)
Affinity DataIC50: 47.5nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Celon Pharma

US Patent
LigandPNGBDBM509516(US11072619, Example 2)
Affinity DataIC50: 59.3nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Celon Pharma

US Patent
LigandPNGBDBM509525(US11072619, Example 9)
Affinity DataIC50: 89.6nMAssay Description:Tested compounds were dissolved in 100% DMSO, and obtained stock solutions were serially diluted in the reaction buffer (50 mM Tris pH 7.5, 10 mM MgC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/7/2022
Entry Details
US Patent